Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second cause of
cancer-related deaths by 2020. Although it has traditionally been approached as a disease …

Background Different histological and molecular subtypes of pancreatic ductal
adenocarcinoma (PDAC), with different molecular composition and survival statistics, have …

Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Introduction Transcriptional analyses have identified several distinct molecular subtypes in
pancreatic ductal adenocarcinoma (PDAC) that have prognostic and potential therapeutic …

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer related death in the world with a five-year survival rate of less than 5%. Not all PDAC …

Simple Summary Although much progress has been made in recent years in the clinical
management of solid tumors, pancreatic ductal adenocarcinoma (PDAC) remains a …

Purpose: Molecular subtyping for pancreatic cancer has made substantial progress in recent
years, facilitating the optimization of existing therapeutic approaches to improve clinical …

Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the
seventh most common cause of cancer death in the world, with the highest mortality rates in …

Pancreatic ductal adenocarcinoma (PDAC) remains a major health problem because it
induces almost systematic mortality. Carcinogenesis begins with genetic aberrations which …

Substantial progress in recent years has dramatically increased our knowledge of the
molecular basis of cancer, revealing new potential therapeutic targets and paving the way …